A phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a high-affinity mu-opioid receptor antagonist) in premenopausal women diagnosed with female sexual arousal disorder (FSAD)

Miguel Orri; Lucy Abraham; Annamaria Giraldi

doi:10.1111/jsm.12071

A phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a high-affinity mu-opioid receptor antagonist) in premenopausal women diagnosed with female sexual arousal disorder (FSAD)

Miguel Orri, Lucy Abraham, Annamaria Giraldi

Psychiatric Centre Copenhagen

9 Citations (Scopus)

Abstract

Female sexual arousal disorder (FSAD) is a condition that can affect women of all ages and have a significant negative impact on emotional well-being.

Original language	English
Journal	The journal of sexual medicine
Volume	10
Issue number	10
Pages (from-to)	2484-96
Number of pages	13
ISSN	1743-6095
DOIs	https://doi.org/10.1111/jsm.12071
Publication status	Published - Oct 2013

Access to Document

10.1111/jsm.12071

Fingerprint

Dive into the research topics of 'A phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a high-affinity mu-opioid receptor antagonist) in premenopausal women diagnosed with female sexual arousal disorder (FSAD)'. Together they form a unique fingerprint.

Cite this

Orri, M., Abraham, L., & Giraldi, A. (2013). A phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a high-affinity mu-opioid receptor antagonist) in premenopausal women diagnosed with female sexual arousal disorder (FSAD). The journal of sexual medicine, 10(10), 2484-96. https://doi.org/10.1111/jsm.12071

A phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a high-affinity mu-opioid receptor antagonist) in premenopausal women diagnosed with female sexual arousal disorder (FSAD). / Orri, Miguel; Abraham, Lucy; Giraldi, Annamaria.

In: The journal of sexual medicine, Vol. 10, No. 10, 10.2013, p. 2484-96.

Research output: Contribution to journal › Journal article › Research › peer-review

Orri, M, Abraham, L & Giraldi, A 2013, 'A phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a high-affinity mu-opioid receptor antagonist) in premenopausal women diagnosed with female sexual arousal disorder (FSAD)', The journal of sexual medicine, vol. 10, no. 10, pp. 2484-96. https://doi.org/10.1111/jsm.12071

Orri M, Abraham L, Giraldi A. A phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a high-affinity mu-opioid receptor antagonist) in premenopausal women diagnosed with female sexual arousal disorder (FSAD). The journal of sexual medicine. 2013 Oct;10(10):2484-96. https://doi.org/10.1111/jsm.12071

Orri, Miguel ; Abraham, Lucy ; Giraldi, Annamaria. / A phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a high-affinity mu-opioid receptor antagonist) in premenopausal women diagnosed with female sexual arousal disorder (FSAD). In: The journal of sexual medicine. 2013 ; Vol. 10, No. 10. pp. 2484-96.

@article{4db011e9389742c08f7575d62fee0fd7,

title = "A phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a high-affinity mu-opioid receptor antagonist) in premenopausal women diagnosed with female sexual arousal disorder (FSAD)",

abstract = "Female sexual arousal disorder (FSAD) is a condition that can affect women of all ages and have a significant negative impact on emotional well-being.",

author = "Miguel Orri and Lucy Abraham and Annamaria Giraldi",

note = "{\textcopyright} 2013 International Society for Sexual Medicine.",

year = "2013",

month = oct,

doi = "10.1111/jsm.12071",

language = "English",

volume = "10",

pages = "2484--96",

journal = "Journal of Sexual Medicine",

issn = "1743-6095",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "10",

}

TY - JOUR

T1 - A phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a high-affinity mu-opioid receptor antagonist) in premenopausal women diagnosed with female sexual arousal disorder (FSAD)

AU - Orri, Miguel

AU - Abraham, Lucy

AU - Giraldi, Annamaria

PY - 2013/10

Y1 - 2013/10

N2 - Female sexual arousal disorder (FSAD) is a condition that can affect women of all ages and have a significant negative impact on emotional well-being.

AB - Female sexual arousal disorder (FSAD) is a condition that can affect women of all ages and have a significant negative impact on emotional well-being.

U2 - 10.1111/jsm.12071

DO - 10.1111/jsm.12071

M3 - Journal article

C2 - 23347610

VL - 10

SP - 2484

EP - 2496

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 10

ER -